Literature DB >> 17374824

Scalpels, beams, drugs, and dreams: challenges of stage IIIA-N2 non-small-cell lung cancer.

David H Johnson, Valerie W Rusch, Andrew T Turrisi.   

Abstract

Entities:  

Mesh:

Year:  2007        PMID: 17374824     DOI: 10.1093/jnci/djk107

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  5 in total

1.  Randomized controlled trials of induction treatment and surgery versus combined chemotherapy and radiotherapy in stages IIIA-N2 NSCLC: a systematic review and meta-analysis.

Authors:  Zuen Ren; Shijie Zhou; Zhidong Liu; Shaofa Xu
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

2.  Prognostic value of lymph node ratio after induction therapy in stage IIIA/N2 non-small cell lung cancer: a monocentric clinical study.

Authors:  Benedikt Haager; Sebastian Wiesemann; Bernward Passlick; Severin Schmid
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

Review 3.  Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment.

Authors:  Debora Brascia; Giulia De Iaco; Marcella Schiavone; Teodora Panza; Francesca Signore; Alessandro Geronimo; Doroty Sampietro; Michele Montrone; Domenico Galetta; Giuseppe Marulli
Journal:  Cancers (Basel)       Date:  2020-07-25       Impact factor: 6.639

4.  Prognostic Factors of IIIAN2 Non-Small-Cell Lung Cancer after Complete Resection: A Systemic Review and Meta-analysis.

Authors:  Youyu Wang; Yanhui Wan; Youhui Qian
Journal:  Comput Math Methods Med       Date:  2021-12-13       Impact factor: 2.238

5.  Outcomes of patients with unresected stage III and stage IV non-small cell lung cancer: A single institution experience.

Authors:  Manpreet Singh Tiwana; Hsueh Ni Lee; Sunil Saini; S K Verma; Meenu Gupta; Madhur Gupta; Navneet Jain; Girish Sindhwani; Jagdish Rawat; Manju Saini; Neena Chauhan; Dushyant Gaur
Journal:  Lung India       Date:  2013-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.